Navigation Links
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter Financial Results and Provide a Clinical Program Update on May 6, 2008
Date:4/30/2008

SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its first quarter financial results before the market opens on Tuesday, May 6, 2008.

Cadence management will host a conference call and live webcast to discuss the financial results and provide a clinical program update on Tuesday, May 6, 2008 at 5:30 am Pacific Time (8:30 am Eastern Time). Interested investors may participate in the conference call by dialing 877-675-4750 (domestic) or 719-325-4865 (international). To access the webcast, please visit the company's website at http://www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, including intravenous acetaminophen (IV acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% aqueous gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM) and Omigard(T
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results and Provides Corporate and Clinical Program Overview
2. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
3. Cadence Pharmaceuticals Chief Medical Officer James Breitmeyer to Present at JMP Securities Healthcare Focus Conference
4. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
5. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
6. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
7. Agreement Executed for Amneal Pharmaceuticals to Acquire the Assets of Interpharm Holdings
8. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
9. Onyx Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
10. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
11. Jazz Pharmaceuticals to Present at Morgan Stanley Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Tara Haelle HealthDay ... -- Measuring how quickly a child,s brain processes sounds ... a new study. Observing children,s brainwaves may ... possible, the study authors reported. "The finding that ... associated with autism severity is hugely promising," said senior ...
(Date:9/22/2014)... “The Race is On!” for the 22nd Susan G. ... 2014 as it moves to its new location at Cesar ... fundraising and awareness event for Susan G. Komen® Central and ... the Cure provides supporters of all ages an opportunity to ... in. , “Moving the Race to Cesar Chavez Plaza ...
(Date:9/22/2014)... Mich. Many parents whose kids participate in athletics ... education, but that,s not enough to ensure parents are ... University of Michigan C.S. Mott Children,s Hospital National Poll ... of the 912 parents of middle and high school ... education: , , 23% have read a brochure ...
(Date:9/22/2014)... step for securing critical information systems, such as ... have created a new approach to computer security ... a terminal and automatically logs them out when ... to use their terminal. , Dartmouth,s Trustworthy ... their findings at the IEEE Symposium ...
(Date:9/22/2014)... to laser weapons, the Office of Naval Research (ONR) ... Modern Day Marine exposition that will prepare Marines as ... , ONR program officers will be in Booth No. ... Corps Base Quantico, to discuss how their research contributes ... "fast, austere and lethal." , ONR,s Expeditionary Maneuver Warfare ...
Breaking Medicine News(10 mins):Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 2Health News:22nd Annual Susan G. Komen Phoenix Race for the Cure® 2014 Moves to Downtown Phoenix 3Health News:Some concussion education more useful than others, parents say 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 2Health News:Dartmouth's new ZEBRA bracelet strengthens computer security 3Health News:Modern Day Marine: ONR features technology for marines of the future 2
... causes epileptic seizures, but researchers from Melbournes Howard Florey ... with the help of their newly developed genetically modified ... mutation based mouse model in the world that mimics ... Dr Steven Petrou and his team to understand the ...
... the University of Pennsylvania School of Medicine have found ... the prognosis of patients with head and neck cancers. ... of CANCER. , The belief that a patients psychological ... cancer is one that has been prominent among patients ...
... upbeat, less positive patients , , MONDAY, Oct. 22 (HealthDay ... how long a person with cancer will survive, a ... that among head and neck cancer patients, emotional health ... factor affecting prognosis. , "We anticipated finding that emotional ...
... Sold Exclusively by GE Healthcare Expands Company ... Offerings within Worldwide Hospital Market, ... CSCX ), a global leader in advanced cardiac monitoring,and ... and has begun full shipments of its new "crash ...
... a prescription NSAID (non-steroidal anti- inflammatory drug) treatment that can be applied directly to ... osteoarthritis pain ... in both the knees and the joints ... of the hands * Offers highly effective ...
... and Item finalize settlement agreement with Teva, ... 22 Astellas,Pharma Inc. ("Astellas"; headquarters: Tokyo; ... ("King"; NYSE: KG) and Teva,Pharmaceutical Industries Ltd. ... of Astellas, along with Item Development AB ...
Cached Medicine News:Health News:Childhood epilepsy research offers new hope for seizure control 2Health News:Penn researchers find emotional well-being has no influence on cancer survival 2Health News:Emotional State Doesn't Affect Cancer Survival 2Health News:Emotional State Doesn't Affect Cancer Survival 3Health News:Emotional State Doesn't Affect Cancer Survival 4Health News:Emotional State Doesn't Affect Cancer Survival 5Health News:Cardiac Science Announces Full Shipment of 'Crash Cart' Defibrillator 2Health News:Cardiac Science Announces Full Shipment of 'Crash Cart' Defibrillator 3Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 2Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 3Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 4Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 5Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 6Health News:Adenoscan(R) Patent Lawsuits Settled 2Health News:Adenoscan(R) Patent Lawsuits Settled 3Health News:Adenoscan(R) Patent Lawsuits Settled 4
(Date:9/22/2014)... NEW YORK , Sept. 22, 2014 ... signed an exclusive, global license agreement with Plasma ... of its proprietary plasma fractionation process. Concurrently, the ... its intention to strategically refocus and rebrand the ... to pursue a national listing for its common ...
(Date:9/22/2014)... cancer is the second leading cause of cancer death ... early - the problem is that too often it ... Education Council (PCEC), – a national organization committed ... screening –  is sponsoring its 25 th Annual ... Committed to encouraging men to take a ...
(Date:9/22/2014)... -- CytRx Corporation (Nasdaq: CYTR ), a ... announced that study designs and progress from two of ... global Phase 3 clinical trial in relapsed/refractory soft tissue ... in small cell lung cancer, will be presented at ... being held September 26-30, in Madrid, Spain ...
Breaking Medicine Technology:Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 2Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 3Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 4Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 5Access Pharmaceuticals Announces Exclusive Global Plasma Therapeutics License, New Management And New Corporate Name 6PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 2PCEC Encourages Men Across America to Have a Baseline Prostate Health Assessment During the Annual Prostate Cancer Awareness Week 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTT/1P chairs are recommended for the ... room, static control, health care and ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... chairs are recommended for the following ... static control, health care and office. ...
... ergonomic chairs with concave seats ... support • Select options like ... and glides. • BTT/1P chairs ... environments: industry, education, laboratory, clean ...
Medicine Products: